(Q37862237)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

Galectin-1 and immunotherapy for brain cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

Steven De Vleeschouwer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Tina Verschuere

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Florence Lefranc

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Robert Kiss

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Stefaan W Van Gool

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

533-543

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21469926%20AND%20SRC:MED&resulttype=core&format=json

The 2007 WHO classification of tumours of the central nervous system

27 January 2020

cites work

1 reference

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

Galectins as modulators of tumour progression

21 January 2018

1 reference

Galectin-1 as a potential cancer target

21 January 2018

1 reference

An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer

21 January 2018

1 reference

The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders

21 January 2018

1 reference

Galectins: structure, function and therapeutic potential

21 January 2018

1 reference

Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism

21 January 2018

1 reference

Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma.

21 January 2018

1 reference

Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development

21 January 2018

1 reference

Immune defects observed in patients with primary malignant brain tumors

21 January 2018

1 reference

CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo

21 January 2018

1 reference

Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments.

21 January 2018

1 reference

Apoptosis of T cells mediated by galectin-1.

21 January 2018

1 reference

Galectin-1 supports survival of naive T cells without promoting cell proliferation

21 January 2018

1 reference

Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells

21 January 2018

1 reference

T cell apoptosis at the maternal-fetal interface in early human pregnancy, involvement of galectin-1.

21 January 2018

1 reference

Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation.

21 January 2018

1 reference

CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death.

21 January 2018

1 reference

Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells

21 January 2018

1 reference

Role of p56lck and ZAP70-mediated tyrosine phosphorylation in galectin-1-induced cell death

21 January 2018

1 reference

Acid sphingomyelinase mediated release of ceramide is essential to trigger the mitochondrial pathway of apoptosis by galectin-1.

21 January 2018

1 reference

Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death

21 January 2018

1 reference

Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane

21 January 2018

1 reference

O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1.

21 January 2018

1 reference

Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death

21 January 2018

1 reference

The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death

21 January 2018

1 reference

Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1.

21 January 2018

1 reference

Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size

21 January 2018

1 reference

Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction

21 January 2018

1 reference

Suppression of autoimmune diabetes by soluble galectin-1

21 January 2018

1 reference

Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis

21 January 2018

1 reference

Galectin-1 suppresses experimental colitis in mice

21 January 2018

1 reference

Strongly enhanced IL-10 production using stable galectin-1 homodimers

21 January 2018

1 reference

A pivotal role for galectin-1 in fetomaternal tolerance

21 January 2018

1 reference

Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function

21 January 2018

1 reference

Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells.

21 January 2018

1 reference

Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis.

21 January 2018

1 reference

The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

21 January 2018

1 reference

Antigen presentation and T cell stimulation by dendritic cells

21 January 2018

1 reference

Tolerogenic dendritic cells

21 January 2018

1 reference

Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions.

21 January 2018

1 reference

Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling

21 January 2018

1 reference

Galectin-1-matured human monocyte-derived dendritic cells have enhanced migration through extracellular matrix

21 January 2018

1 reference

Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice.

21 January 2018

1 reference

The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses

21 January 2018

1 reference

Distribution and characterization of microglia/macrophages in human brain tumors.

21 January 2018

1 reference

Macrophage polarization in tumour progression

21 January 2018

1 reference

Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages

21 January 2018

1 reference

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

21 January 2018

1 reference

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

Dendritic cell therapy of high-grade gliomas.

21 January 2018

1 reference

Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells.

21 January 2018

1 reference

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients

21 January 2018

1 reference

Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview

21 January 2018

1 reference

Combating immunosuppression in glioma

21 January 2018

1 reference

Immunotherapy of diffuse gliomas: biological background, current status and future developments

21 January 2018

1 reference

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

21 January 2018

Galectins and gliomas

1 reference

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege

21 January 2018

1 reference

Galectin-1: a link between tumor hypoxia and tumor immune privilege

21 January 2018

1 reference

Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma.

21 January 2018

1 reference

Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape.

21 January 2018

1 reference

Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response

21 January 2018

1 reference

Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model

21 January 2018

1 reference

Anti-galectin compounds as potential anti-cancer drugs

21 January 2018

1 reference

Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas.

21 January 2018

1 reference

Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas.

21 January 2018

1 reference

Expression pattern of galectin-3 in neural tumor cell lines

21 January 2018

1 reference

Glioma-associated cancer-initiating cells induce immunosuppression

21 January 2018

1 reference

Multifaceted role of galectin-3 on human glioblastoma cell motility

21 January 2018

1 reference

Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis

21 January 2018

1 reference

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures

21 January 2018

1 reference

The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain

21 January 2018

1 reference

A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice

21 January 2018

1 reference

Tumor cells secrete galectin-1 to enhance endothelial cell activity.

21 January 2018

1 reference

Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model

21 January 2018

1 reference

Evidence of galectin-1 involvement in glioma chemoresistance

21 January 2018

1 reference

Approaches for the sequence-specific knockdown of mRNA.

21 January 2018

1 reference

Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer

21 January 2018

1 reference

Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration

21 January 2018

1 reference